Evidence map›Paper›PMID 38776418›Full record

ArticleACS applied bio materials2024

Hyaluronic Acid-Coated Silica Nanoparticles for Targeted Delivery of Nitric Oxide to Cancer Cells.

Quincy E Grayton, Tien T Phan, Caden C Kussatz, Mark H Schoenfisch

Abstract read
In one paragraph

Article in ACS applied bio materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Nitric oxide-releasing hyaluronic acid therapeutics for treating periodontal diseaseR01DE032060 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark H Schoenfisch, Shannon Margaret Wallet · 2023 to 2026
$2.0M
Nitric oxide-releasing glycosaminoglycans for treating complex woundsR01DK132778 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark H Schoenfisch, Shannon Margaret Wallet · 2023 to 2026
$1.5M
Andor Dragonfly 202 Spinning Disk Confocal Microscope for the University of North Carolina at Chapel HillS10OD030223 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ARIEL, PABLO · 2021 to 2021
$474k
NCI NIH HHS P30 CA016086NIDCR NIH HHS R01 DE032060NIDDK NIH HHS R01 DK132778NIH HHS S10 OD030223
6 · The paper itself

Abstract

Drug resistance and off-target toxicity are two of the greatest challenges to chemotherapeutic melanoma treatments. Nitric oxide (NO) represents an attractive alternative to conventional therapeutics due to its numerous anticancer properties and low probability of engendering resistance. As NO is highly reactive, macromolecular NO donors are needed for the controlled and targeted delivery of NO for therapeutic applications. Herein, mesoporous silica nanoparticles (MSNs) coated with hyaluronic acid (HA) were developed as a NO delivery system to facilitate controlled delivery to cancer cells through both passive and active targeting via the enhanced permeation and retention effect and directed binding of HA with CD44 receptors, respectively. The aminosilane modification, HA concentration, and HA molecular weight were systematically evaluated to facilitate the MSN coating and NO loading. The hydrodynamic diameter and dispersity of the nanoparticles increased after HA coating due to the hydrophilic nature of HA, with greater increases observed at higher HA molecular weight. Lower starting concentrations of HA and aminosilanes with longer alkyl chains favored more efficient HA coating. Faster NO-release kinetics and lower NO payloads were observed for the HA-coated MSNs relative to uncoated MSNs. However, the localized delivery of NO to cancer cells through the active targeting conferred by HA increased levels of oxidative stress and induced mitochondria-mediated apoptosis in melanoma cells. Cytotoxicity was also evaluated against human dermal fibroblasts, with the use of 6 kDa HA-coated MSNs resulting in the greatest therapeutic indices. Enhanced internalization of HA-coated nanoparticles into melanoma cells versus uncoated nanoparticles was visualized with confocal microscopy and quantified by fluorescence spectroscopy. In total, HA-coated MSNs represent a promising NO delivery system for potential use as a chemotherapeutic for skin melanomas.

Indexed as

Hyaluronic AcidMaterials TestingNanoparticlesNitric OxideParticle SizeSilicon DioxideAntineoplastic AgentsBiocompatible MaterialsCell Line, TumorCell ProliferationCell SurvivalDrug Delivery SystemsDrug Screening Assays, AntitumorHumansAntineoplastic AgentsBiocompatible MaterialsHyaluronic AcidNitric OxideSilicon Dioxidehyaluronic acid-coated nanoparticlesmelanomamesoporous silica nanoparticlesnitric oxidetargeted drug delivery

Identifiers

PMID38776418
PMCPMC11546759

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.